

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/743,891	12/22/2003	Jonathan P. Duvick	P05573US04-PHI 1134RD 2479  EXAMINER	
27142 7	08/18/2006			
MCKEE, VOORHEES & SEASE, P.L.C.			IBRAHIM, MEDINA AHMED	
ATTN: PIONEER HI-BRED 801 GRAND AVENUE, SUITE 3200			ART UNIT	PAPER NUMBER
DES MOINES	, IA 50309-2721		1638	
			DATE MAILED: 08/18/2006	;

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/743,891	DUVICK ET AL.			
Office Action Summary	Examiner	Art Unit			
	Medina A. Ibrahim	1638			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timwill apply and will expire SIX (6) MONTHS from a cause the application to become ARANDONE.	N. nely filed the mailing date of this communication. D. (35.U.S.C. 8.133)			
Status					
1)⊠ Responsive to communication(s) filed on <u>01 Ju</u>	<u>une 2004</u> .				
2a) This action is <b>FINAL</b> . 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.			
Disposition of Claims					
4)  Claim(s) 1-11 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5)  Claim(s) is/are allowed. 6)  Claim(s) is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) 1-11 are subject to restriction and/or expressions.	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the Education of the Education of the drawing of the d	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date  U.S. Patent and Trademark Office PTOL-326 (Rev. 7-05)	6) Other:				
,					

Art Unit: 1638

## **DETAILED ACTION**

Page 2

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-10, drawn to an isolated polynucleotide, a recombinant vector, host cell/ plant comprising said polynucleotide, classified in class 800, subclass 279, for example.
- II. Claim 11, drawn to an isolated APAO polypeptide, classified in class 530, subclass 370, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-II are patentably distinct products. The protein of group II and polynucleotide of group I are patentably distinct inventions for the following reasons. Proteins, which are composed of amino acids, and polynucleotides, which are composed of purine and pyrimidine units, are structurally distinct molecules; any relationship between a polynucleotide and protein is dependent upon the information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded protein. In the present claims, a polynucleotide of group I does not necessarily encode a protein of group II. For example, the polynucleotide of claim 1 (a) would not encode the polypeptide of claim 10 (a). In addition, while a protein of group II can made by methods using some, but not all, of the polynucleotides that fall within the scope of group I, it can also be recovered from a natural source using by biochemical means. For instance, the protein can be isolated using affinity chromatography. For these reasons, the inventions of groups I and II are

Application/Control Number: 10/743,891

Art Unit: 1638

patentably distinct.

1. Furthermore, searching the inventions of groups I and II together would impose a serious search burden. In the instant case, the search of the proteins and the polynucleotides are not coextensive. The inventions of Groups I and II have a separate status in the art as shown by their different classifications. In cases such as this one where descriptive sequence information is provided, the sequences are searched in appropriate databases. There is search burden also in the non-patent literature. Prior to the concomitant isolation and expression of the sequence of interest there may be journal articles devoted solely to proteins which would not have described the polynucleotide. Similarly, there may have been "classical" genetics papers which had no knowledge of the protein but spoke to the gene. Searching, therefore is not coextensive. In addition, the protein claims include proteins having 90% identity to the sequence identified. This search requires an extensive analysis of the art retrieved in a sequence search and will require an in-depth analysis of technical literature. The scope of polynucleotide as claimed extend beyond the polynucleotide that encodes the claimed proteins as explained above, which is not likely to result in relevant art with respect to the protein of group II. As such, it would be burdensome to search the inventions of groups I and II together.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Page 3

Application/Control Number: 10/743,891

Art Unit: 1638

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Because these inventions are distinct for the reasons set forth above and have acquired a separate status in the art as shown by their different classifications and their recognized divergent subject matter and because the literature search required for the groups is not coextensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by

Application/Control Number: 10/743,891

Art Unit: 1638

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Medina A. Ibrahim whose telephone number is (571) 272-0797. The Examiner can normally be reached Monday -Thursday from 8:00AM to 5:30PM and every other Friday from 9:00AM to 5:00 PM. Before and after final responses should be directed to fax nos. (703) 872-9306 and (703) 872-9307, respectively.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0795.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

8/4/06

MAI

MEDINA A. IBRAHIM

Page 5

PRIMARY EXAMINER Oding Alball